DSCR10: A Potential Drug Target and Biomarker for Down syndrome

Target Name: DSCR10

NCBI ID: G259234

DSCR10

Other Name(s): Down syndrome critical region 10

DSCR10: A Potential Drug Target and Biomarker for Down syndrome

Down syndrome is a complex neurodevelopmental disorder that affects approximately 1 in 70 people worldwide. It is characterized by a range of developmental delays, including intellectual disabilities, motor impairments, and unique facial features. Despite these challenges, many individuals with Down syndrome are capable of leading fulfilling lives and achieving their goals. One potential approach to treating Down syndrome is to target the DSCR10 gene, which has been identified as a potential drug target and biomarker for the disorder.

The DSCR10 gene

The DSCR10 gene is located on chromosome 21 and is responsible for the production of a protein known as DSCR10. This protein plays a crucial role in the development and maintenance of normal brain function, including the formation of neural connections and the regulation of ion channels. DSCR10 dysfunction has been linked to a range of neurodevelopmental disorders, including Down syndrome.

DSCR10 as a drug target

The potential drug target for DSCR10 is based on its role in normal brain function and the symptoms associated with DSCR10 dysfunction. Studies have shown that individuals with Down syndrome have reduced levels of DSCR10 in their brains, which could make them more susceptible to drugs that target this protein. Additionally, the fact that DSCR10 is involved in the regulation of neural circuits suggests that drugs that modify DSCR10 activity could potentially improve neural function and reduce the symptoms of Down syndrome.

DSCR10 as a biomarker

In addition to its potential as a drug target, DSCR10 is also a potential biomarker for Down syndrome. The DSCR10 gene has been identified as a potential biomarker for the disorder, with higher levels of DSCR10 being associated with an increased risk of Down syndrome. This suggests that DSCR10 levels could be used as a diagnostic marker for Down syndrome, with lower levels of DSCR10 indicating an increased risk of the disorder.

Methods for studying DSCR10

Studies on DSCR10 have been conducted in a variety of organisms, including mice, with the goal of understanding its role in normal brain function and the development of neurodevelopmental disorders. These studies have shown that DSCR10 is involved in the regulation of neural circuits and that it plays a role in the development of memory and learning.

In addition to its role in neural circuits, DSCR10 is also involved in the regulation of ion channels and intracellular signaling pathways. These studies suggest that DSCR10 dysfunction could contribute to the symptoms of Down syndrome, including cognitive impairments and motor impairments.

Conclusion

DSCR10 is a gene that has been identified as a potential drug target and biomarker for Down syndrome. Its role in the regulation of normal brain function and its involvement in the development of neurodevelopmental disorders make it an attractive target for drug development. Further research is needed to fully understand the role of DSCR10 in the development and treatment of Down syndrome.

Protein Name: Down Syndrome Critical Region 10

The "DSCR10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSCR10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets